|Articles|February 1, 2001
Oncology NEWS International
- Oncology NEWS International Vol 10 No 2
- Volume 10
- Issue 2
HER-2 Predicts Complete Pathologic Response to Chemo Neoadjuvant Chemotherapy
The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.
Advertisement
Optimal Care for HER2+ Breast Cancer
An interactive case challenge activity.
The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.
Go to Activity
Articles in this issue
over 25 years ago
Activated T Cells Can Alter Behavior of Leukemic B Cellsover 25 years ago
Response Continues for at Least 8 Months with Ibritumomab Tiuxetanover 25 years ago
Synthetic Anthracycline Produces High Response Rates in SCLCover 25 years ago
Ibritumomab Tiuxetan Produces 73% Response Rate in B-cell NHLover 25 years ago
G-CSF Might Prolong Rituximab Responses in NHLover 25 years ago
Use of CAD Increases the Early Detection of Breast Cancer by 20%Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Where Does LAG-3/PD-1 Inhibition Fit In PD-1–Refractory Hodgkin Lymphoma?
2
VS-7375 Exhibits Activity in KRAS G12D–Mutated Solid Tumors
3
GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations
4
Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications
5